| Autor: |
Chouljenko DV; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Ding J; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Lee IF; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Murad YM; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Bu X; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Liu G; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Delwar Z; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Sun Y; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Yu S; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Samudio I; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Zhao R; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada., Jia WW; Virogin Biotech Canada Ltd., 408-3800 Wesbrook Mall, Vancouver, BC V6S 2L9, Canada. |
| Abstrakt: |
Oncolytic virotherapy is a promising new tool for cancer treatment, but direct lytic destruction of tumor cells is not sufficient and must be accompanied by strong immune activation to elicit anti-tumor immunity. We report here the creation of a novel replication-competent recombinant oncolytic herpes simplex virus type 1 (VG161) that carries genes coding for IL-12, IL-15, and IL-15 receptor alpha subunit, along with a peptide fusion protein capable of disrupting PD-1/PD-L1 interactions. The VG161 virus replicates efficiently and exhibits robust cytotoxicity in multiple tumor cell lines. Moreover, the encoded cytokines and the PD-L1 blocking peptide work cooperatively to boost immune cell function. In vivo testing in syngeneic CT26 and A20 tumor models reveals superior efficacy when compared to a backbone virus that does not express exogenous genes. Intratumoral injection of VG161 induces abscopal responses in non-injected distal tumors and grants resistance to tumor re-challenge. The robust anti-tumor effect of VG161 is associated with T cell and NK cell tumor infiltration, expression of Th1 associated genes in the injection site, and increased frequency of splenic tumor-specific T cells. VG161 also displayed a superb safety profile in GLP acute and repeated injection toxicity studies performed using cynomolgus monkeys. Overall, we demonstrate that VG161 can induce robust oncolysis and stimulate a robust anti-tumor immune response without sacrificing safety. |
